{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:25:38Z","timestamp":1794360338973,"version":"4.9.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Aberrant activity of histone deacetylases (HDACs) is a pathological phenomenon in several diseases, including Duchenne muscular dystrophy (DMD). In DMD, the upregulation of HDACs is driven by the disassembly of the dystrophin-associated protein complex (DAPC), which, under normal physiological conditions, provides mechanical stability to muscle fibres and acts as a signalling hub anchoring signalling proteins and molecules to their functional sites. In dystrophic muscle, DAPC disassembly causes delocalisation of signalling proteins and, therefore, disrupts signalling pathways. Displacement of epigenetic signalling molecules leads to the uncontrolled activity of HDACs and excessive removal of acetyl groups from histone proteins. Consequently, chromatin becomes tightly bound, preventing the expression of genes involved in muscle homeostasis. The pathological consequences of increased HDAC activity extend beyond muscle fibres, affecting several cell types, translating into a chronically activated immune system, promoting fibrotic and adipose tissue formation and impairing muscle regeneration. Here, we review the current evidence implicating HDACs as a key driver in DMD disease development and progression. We describe the mechanism of HDAC overactivity and the downstream consequences that contribute to the pathogenesis of the disease by disrupting muscle repair and regeneration. Finally, we highlight HDACs as targets for inhibition, offering a novel therapeutic strategy to counteract the multiple pathological events in DMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-025-02031-7","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T02:44:16Z","timestamp":1764816256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Histone deacetylases in Duchenne muscular dystrophy: a role in the mechanism of disease and a target for inhibition"],"prefix":"10.1186","volume":"18","author":[{"given":"Mariarita","family":"Bertoldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Albamonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"D\u2019amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Nigro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Panicucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sframeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"3","key":"2031_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251\u201367.","journal-title":"Lancet Neurol"},{"issue":"4","key":"2031_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1212\/WNL.0000000000002891","volume":"87","author":"L Bello","year":"2016","unstructured":"Bello L, Morgenroth LP, Gordish-Dressman H, Hoffman EP, McDonald CM, Cirak S. DMD genotypes and loss of ambulation in the CINRG Duchenne natural history study. Neurology. 2016;87(4):401\u20139.","journal-title":"Neurology"},{"issue":"4","key":"2031_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347\u201361.","journal-title":"Lancet Neurol"},{"issue":"7","key":"2031_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","volume":"35","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J, Lochm\u00fcller H. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(7):643\u201353.","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"2031_CR5","volume":"33","author":"P Dowling","year":"2023","unstructured":"Dowling P, Swandulla D, Ohlendieck K. Cellular pathogenesis of Duchenne muscular dystrophy: progressive myofibre degeneration, chronic inflammation, reactive myofibrosis and satellite cell dysfunction. Eur J Transl Myol. 2023;33(4):11856.","journal-title":"Eur J Transl Myol"},{"key":"2031_CR6","doi-asserted-by":"publisher","first-page":"1180980","DOI":"10.3389\/fphys.2023.1180980","volume":"14","author":"K Kodippili","year":"2023","unstructured":"Kodippili K, Rudnicki MA. Satellite cell contribution to disease pathology in Duchenne muscular dystrophy. Front Physiol. 2023;14:1180980.","journal-title":"Front Physiol"},{"issue":"49","key":"2031_CR7","doi-asserted-by":"publisher","first-page":"19183","DOI":"10.1073\/pnas.0805514105","volume":"105","author":"C Colussi","year":"2008","unstructured":"Colussi C, Mozzetta C, Gurtner A, Illi B, Rosati J, Straino S, et al. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA. 2008;105(49):19183\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2031_CR8","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202254721","volume":"23","author":"S Consalvi","year":"2022","unstructured":"Consalvi S, Tucciarone L, Macr\u00ec E, De Bardi M, Picozza M, Salvatori I, et al. Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibro-adipogenic progenitors. EMBO Rep. 2022;23(6):e54721.","journal-title":"EMBO Rep"},{"issue":"5","key":"2031_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/genes11050556","volume":"11","author":"G Milazzo","year":"2020","unstructured":"Milazzo G, Mercatelli D, Di Muzio G, Triboli L, De Rosa P, Perini G, et al. Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability. Genes. 2020;11(5):556.","journal-title":"Genes"},{"key":"2031_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054306","author":"M Sandon\u00e0","year":"2023","unstructured":"Sandon\u00e0 M, Cavioli G, Renzini A, Cedola A, Gigli G, Coletti D, et al. Histone deacetylases: molecular mechanisms and therapeutic implications for muscular dystrophies. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24054306.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2031_CR11","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/jcsm.12891","volume":"13","author":"A Renzini","year":"2022","unstructured":"Renzini A, Marroncelli N, Cavioli G, Di Francescantonio S, Forcina L, Lambridis A, et al. Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle. 2022;13(2):1339\u201359.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2031_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105750","volume":"170","author":"M Spreafico","year":"2021","unstructured":"Spreafico M, Cafora M, Bragato C, Capitanio D, Marasca F, Bodega B, et al. Targeting HDAC8 to ameliorate skeletal muscle differentiation in Duchenne muscular dystrophy. Pharmacol Res. 2021;170:105750.","journal-title":"Pharmacol Res"},{"issue":"7","key":"2031_CR13","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1096\/fj.08-115618","volume":"23","author":"C Colussi","year":"2009","unstructured":"Colussi C, Gurtner A, Rosati J, Illi B, Ragone G, Piaggio G, et al. Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy. FASEB J. 2009;23(7):2131\u201341.","journal-title":"FASEB J"},{"issue":"3","key":"2031_CR14","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.molmed.2024.01.007","volume":"30","author":"C Mozzetta","year":"2024","unstructured":"Mozzetta C, Sartorelli V, Steinkuhler C, Puri PL. HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients. Trends Mol Med. 2024;30(3):278\u201394.","journal-title":"Trends Mol Med"},{"issue":"1","key":"2031_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/mas.21823","volume":"43","author":"EH Canessa","year":"2024","unstructured":"Canessa EH, Spathis R, Novak JS, Beedle A, Nagaraju K, Bello L, et al. Characterization of the dystrophin-associated protein complex by mass spectrometry. Mass Spectrom Rev. 2024;43(1):90\u2013105.","journal-title":"Mass Spectrom Rev"},{"issue":"2","key":"2031_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.bbamem.2013.08.023","volume":"1838","author":"B Constantin","year":"2014","unstructured":"Constantin B. Dystrophin complex functions as a scaffold for signalling proteins. Biochim Biophys Acta. 2014;1838(2):635\u201342.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"2031_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/0092-8674(95)90471-9","volume":"82","author":"JE Brenman","year":"1995","unstructured":"Brenman JE, Chao DS, Xia H, Aldape K, Bredt DS. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell. 1995;82(5):743\u201352.","journal-title":"Cell"},{"issue":"17","key":"2031_CR18","doi-asserted-by":"publisher","first-page":"9142","DOI":"10.1073\/pnas.93.17.9142","volume":"93","author":"WJ Chang","year":"1996","unstructured":"Chang WJ, Iannaccone ST, Lau KS, Masters BS, McCabe TJ, McMillan K, et al. Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc Natl Acad Sci USA. 1996;93(17):9142\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2031_CR19","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1172\/JCI36612","volume":"119","author":"Y Lai","year":"2009","unstructured":"Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C, et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest. 2009;119(3):624\u201335.","journal-title":"J Clin Invest"},{"issue":"21","key":"2031_CR20","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1113\/jphysiol.2014.274878","volume":"592","author":"JG Tidball","year":"2014","unstructured":"Tidball JG, Wehling-Henricks M. Nitric oxide synthase deficiency and the pathophysiology of muscular dystrophy. J Physiol. 2014;592(21):4627\u201338.","journal-title":"J Physiol"},{"issue":"1","key":"2031_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nm.3019","volume":"19","author":"N Ito","year":"2013","unstructured":"Ito N, Ruegg UT, Kudo A, Miyagoe-Suzuki Y, Takeda S. Activation of calcium signaling through Trpv1 by nNOS and peroxynitrite as a key trigger of skeletal muscle hypertrophy. Nat Med. 2013;19(1):101\u20136.","journal-title":"Nat Med"},{"issue":"5","key":"2031_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2108\/zsj.26.315","volume":"26","author":"S Abe","year":"2009","unstructured":"Abe S, Soejima M, Iwanuma O, Saka H, Matsunaga S, Sakiyama K, et al. Expression of myostatin and follistatin in mdx mice, an animal model for muscular dystrophy. Zoolog Sci. 2009;26(5):315\u201320.","journal-title":"Zoolog Sci"},{"issue":"10","key":"2031_CR23","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nm1479","volume":"12","author":"GC Minetti","year":"2006","unstructured":"Minetti GC, Colussi C, Adami R, Serra C, Mozzetta C, Parente V, et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med. 2006;12(10):1147\u201350.","journal-title":"Nat Med"},{"issue":"4","key":"2031_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cmet.2010.07.008","volume":"12","author":"D Cacchiarelli","year":"2010","unstructured":"Cacchiarelli D, Martone J, Girardi E, Cesana M, Incitti T, Morlando M, et al. MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin\/nNOS pathway. Cell Metab. 2010;12(4):341\u201351.","journal-title":"Cell Metab"},{"key":"2031_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1183101","volume":"14","author":"A Bez Batti Angulski","year":"2023","unstructured":"Bez Batti Angulski A, Hosny N, Cohen H, Martin AA, Hahn D, Bauer J, et al. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Front Physiol. 2023;14:1183101.","journal-title":"Front Physiol"},{"issue":"1","key":"2031_CR26","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/hmg\/ddv466","volume":"25","author":"DL Rebolledo","year":"2016","unstructured":"Rebolledo DL, Kim MJ, Whitehead NP, Adams ME, Froehner SC. Sarcolemmal targeting of nNOS\u03bc improves contractile function of mdx muscle. Hum Mol Genet. 2016;25(1):158\u201366.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"2031_CR27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/hmg\/ddu469","volume":"24","author":"SC Froehner","year":"2015","unstructured":"Froehner SC, Reed SM, Anderson KN, Huang PL, Percival JM. Loss of nNOS inhibits compensatory muscle hypertrophy and exacerbates inflammation and eccentric contraction-induced damage in mdx mice. Hum Mol Genet. 2015;24(2):492\u2013505.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2031_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1152\/physrev.00007.2015","volume":"96","author":"DG Allen","year":"2016","unstructured":"Allen DG, Whitehead NP, Froehner SC. Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiol Rev. 2016;96(1):253\u2013305.","journal-title":"Physiol Rev"},{"issue":"2","key":"2031_CR29","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/cdd.2016.127","volume":"24","author":"MC Vila","year":"2017","unstructured":"Vila MC, Rayavarapu S, Hogarth MW, Van der Meulen JH, Horn A, Defour A, et al. Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy. Cell Death Differ. 2017;24(2):330\u201342.","journal-title":"Cell Death Differ"},{"issue":"3","key":"2031_CR30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/jcsm.12405","volume":"10","author":"MC Hughes","year":"2019","unstructured":"Hughes MC, Ramos SV, Turnbull PC, Rebalka IA, Cao A, Monaco CMF, et al. Early myopathy in Duchenne muscular dystrophy is associated with elevated mitochondrial H(2) O(2) emission during impaired oxidative phosphorylation. J Cachexia Sarcopenia Muscle. 2019;10(3):643\u201361.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2031_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105751","volume":"170","author":"M Giovarelli","year":"2021","unstructured":"Giovarelli M, Zecchini S, Catarinella G, Moscheni C, Sartori P, Barbieri C, et al. Givinostat as metabolic enhancer reverting mitochondrial biogenesis deficit in Duchenne muscular dystrophy. Pharmacol Res. 2021;170:105751.","journal-title":"Pharmacol Res"},{"issue":"4","key":"2031_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/0092-8674(88)90463-1","volume":"52","author":"C Webster","year":"1988","unstructured":"Webster C, Silberstein L, Hays AP, Blau HM. Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell. 1988;52(4):503\u201313.","journal-title":"Cell"},{"issue":"4","key":"2031_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.14348\/molcells.2015.2278","volume":"38","author":"TJ Cohen","year":"2015","unstructured":"Cohen TJ, Choi MC, Kapur M, Lira VA, Yan Z, Yao TP. HDAC4 regulates muscle fiber type-specific gene expression programs. Mol Cells. 2015;38(4):343\u20138.","journal-title":"Mol Cells"},{"issue":"9","key":"2031_CR34","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1172\/JCI31960","volume":"117","author":"MJ Potthoff","year":"2007","unstructured":"Potthoff MJ, Wu H, Arnold MA, Shelton JM, Backs J, McAnally J, et al. Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers. J Clin Invest. 2007;117(9):2459\u201367.","journal-title":"J Clin Invest"},{"issue":"5","key":"2031_CR35","doi-asserted-by":"publisher","first-page":"R1173","DOI":"10.1152\/ajpregu.00735.2009","volume":"298","author":"JG Tidball","year":"2010","unstructured":"Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol. 2010;298(5):R1173\u201387.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"6","key":"2031_CR36","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cell.2013.10.054","volume":"155","author":"D Burzyn","year":"2013","unstructured":"Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, et al. A special population of regulatory T cells potentiates muscle repair. Cell. 2013;155(6):1282\u201395.","journal-title":"Cell"},{"issue":"20","key":"2031_CR37","doi-asserted-by":"publisher","first-page":"7065","DOI":"10.1128\/MCB.21.20.7065-7077.2001","volume":"21","author":"BP Ashburner","year":"2001","unstructured":"Ashburner BP, Westerheide SD, Baldwin AS Jr. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol. 2001;21(20):7065\u201377.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"2031_CR38","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1097-2765(02)00477-X","volume":"9","author":"H Zhong","year":"2002","unstructured":"Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP\/p300 or HDAC-1. Mol Cell. 2002;9(3):625\u201336.","journal-title":"Mol Cell"},{"key":"2031_CR39","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/690901","volume":"2012","author":"PV Licciardi","year":"2012","unstructured":"Licciardi PV, Karagiannis TC. Regulation of immune responses by histone deacetylase inhibitors. ISRN Hematol. 2012;2012:690901.","journal-title":"ISRN Hematol"},{"issue":"5","key":"2031_CR40","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.coi.2011.07.002","volume":"23","author":"UH Beier","year":"2011","unstructured":"Beier UH, Akimova T, Liu Y, Wang L, Hancock WW. Histone\/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells. Curr Opin Immunol. 2011;23(5):670\u20138.","journal-title":"Curr Opin Immunol"},{"key":"2031_CR41","doi-asserted-by":"publisher","first-page":"1514898","DOI":"10.3389\/fcell.2024.1514898","volume":"12","author":"A Aartsma-Rus","year":"2025","unstructured":"Aartsma-Rus A. Histone deacetylase inhibition with givinostat: a multi-targeted mode of action with the potential to halt the pathological cascade of Duchenne muscular dystrophy. Front Cell Dev Biol. 2025;12:1514898.","journal-title":"Front Cell Dev Biol"},{"key":"2031_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/B978-0-12-385940-2.00004-8","volume":"96","author":"JM Peterson","year":"2011","unstructured":"Peterson JM, Bakkar N, Guttridge DC. NF-\u03baB signaling in skeletal muscle health and disease. Curr Top Dev Biol. 2011;96:85\u2013119.","journal-title":"Curr Top Dev Biol"},{"issue":"1","key":"2031_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01001-z","volume":"13","author":"A Rugowska","year":"2021","unstructured":"Rugowska A, Starosta A, Konieczny P. Epigenetic modifications in muscle regeneration and progression of Duchenne muscular dystrophy. Clin Epigenet. 2021;13(1):13.","journal-title":"Clin Epigenet"},{"issue":"1","key":"2031_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1462","volume":"12","author":"K Mukund","year":"2020","unstructured":"Mukund K, Subramaniam S. Skeletal muscle: a review of molecular structure and function, in health and disease. Wiley Interdiscip Rev Syst Biol Med. 2020;12(1):e1462.","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"issue":"4","key":"2031_CR45","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1097-2765(01)00373-2","volume":"8","author":"PL Puri","year":"2001","unstructured":"Puri PL, Iezzi S, Stiegler P, Chen TT, Schiltz RL, Muscat GE, et al. Class I histone deacetylases sequentially interact with MyoD and pRb during skeletal myogenesis. Mol Cell. 2001;8(4):885\u201397.","journal-title":"Mol Cell"},{"issue":"26","key":"2031_CR46","doi-asserted-by":"publisher","first-page":"14400","DOI":"10.1073\/pnas.260501497","volume":"97","author":"TA McKinsey","year":"2000","unstructured":"McKinsey TA, Zhang CL, Olson EN. Activation of the myocyte enhancer factor-2 transcription factor by calcium\/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc Natl Acad Sci USA. 2000;97(26):14400\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2031_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2011.00064","volume":"2","author":"AK Marrone","year":"2011","unstructured":"Marrone AK, Shcherbata HR. Dystrophin orchestrates the epigenetic profile of muscle cells via miRNAs. Front Genet. 2011;2:64.","journal-title":"Front Genet"},{"issue":"4","key":"2031_CR48","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/emmm.201202096","volume":"5","author":"C Mozzetta","year":"2013","unstructured":"Mozzetta C, Consalvi S, Saccone V, Tierney M, Diamantini A, Mitchell KJ, et al. Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old mdx mice. EMBO Mol Med. 2013;5(4):626\u201339.","journal-title":"EMBO Mol Med"},{"issue":"2","key":"2031_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/ncb2015","volume":"12","author":"AW Joe","year":"2010","unstructured":"Joe AW, Yi L, Natarajan A, Le Grand F, So L, Wang J, et al. Muscle injury activates resident fibro\/adipogenic progenitors that facilitate myogenesis. Nat Cell Biol. 2010;12(2):153\u201363.","journal-title":"Nat Cell Biol"},{"issue":"Pt 21","key":"2031_CR50","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1242\/jcs.086629","volume":"124","author":"A Uezumi","year":"2011","unstructured":"Uezumi A, Ito T, Morikawa D, Shimizu N, Yoneda T, Segawa M, et al. Fibrosis and adipogenesis originate from a common mesenchymal progenitor in skeletal muscle. J Cell Sci. 2011;124(Pt 21):3654\u201364.","journal-title":"J Cell Sci"},{"issue":"8","key":"2031_CR51","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1101\/gad.234468.113","volume":"28","author":"V Saccone","year":"2014","unstructured":"Saccone V, Consalvi S, Giordani L, Mozzetta C, Barozzi I, Sandon\u00e1 M, et al. HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles. Genes Dev. 2014;28(8):841\u201357.","journal-title":"Genes Dev"},{"issue":"11","key":"2031_CR52","doi-asserted-by":"publisher","first-page":"7757","DOI":"10.1073\/pnas.112218599","volume":"99","author":"S Iezzi","year":"2002","unstructured":"Iezzi S, Cossu G, Nervi C, Sartorelli V, Puri PL. Stage-specific modulation of skeletal myogenesis by inhibitors of nuclear deacetylases. Proc Natl Acad Sci USA. 2002;99(11):7757\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2031_CR53","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1534-5807(04)00107-8","volume":"6","author":"S Iezzi","year":"2004","unstructured":"Iezzi S, Di Padova M, Serra C, Caretti G, Simone C, Maklan E, et al. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell. 2004;6(5):673\u201384.","journal-title":"Dev Cell"},{"key":"2031_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70165","author":"CM McDonald","year":"2025","unstructured":"McDonald CM, Guglieri M, Vu\u010dini\u0107 D, Acsadi G, Brandsema JF, Bruno C, et al. Long-term evaluation of givinostat in Duchenne muscular dystrophy, and natural history comparisons. Ann Clin Transl Neurol. 2025. https:\/\/doi.org\/10.1002\/acn3.70165.","journal-title":"Ann Clin Transl Neurol"},{"key":"2031_CR55","unstructured":"US Food and Drug Administration. DUVYZAT (givinostat) oral suspension, Label. Available at https:\/\/www.accessdata.fda.gov\/2024."},{"key":"2031_CR56","unstructured":"European Medicines Agency. Duvyzat oral suspension, Summary of Product Characteristics. Available at https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/duvyzat2025."},{"key":"2031_CR57","unstructured":"UK Medicines and Healthcare products Regulatory Agency. Duvyzat oral suspension, Summary of Product Characteristics. Available at https:\/\/products.mhra.gov.uk\/2024."},{"issue":"1-12","key":"2031_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2119\/2006-00005.Dinarello","volume":"11","author":"F Leoni","year":"2005","unstructured":"Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005;11(1\u201312):1\u201315.","journal-title":"Mol Med"},{"issue":"1","key":"2031_CR59","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2119\/molmed.2013.00011","volume":"19","author":"S Consalvi","year":"2013","unstructured":"Consalvi S, Mozzetta C, Bettica P, Germani M, Fiorentini F, Del Bene F, et al. Preclinical studies in the mdx mouse model of Duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. Mol Med. 2013;19(1):79\u201387.","journal-title":"Mol Med"},{"issue":"1","key":"2031_CR60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13395-021-00273-6","volume":"11","author":"SA Licandro","year":"2021","unstructured":"Licandro SA, Crippa L, Pomarico R, Perego R, Fossati G, Leoni F, et al. The pan HDAC inhibitor givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene. Skelet Muscle. 2021;11(1):19.","journal-title":"Skelet Muscle"},{"issue":"5-6","key":"2031_CR61","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2119\/molmed.2011.00020","volume":"17","author":"A Furlan","year":"2011","unstructured":"Furlan A, Monzani V, Reznikov LL, Leoni F, Fossati G, Modena D, et al. Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol Med. 2011;17(5\u20136):353\u201362.","journal-title":"Mol Med"},{"issue":"10","key":"2031_CR62","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","volume":"26","author":"P Bettica","year":"2016","unstructured":"Bettica P, Petrini S, D\u2019Oria V, D\u2019Amico A, Catteruccia M, Pane M, et al. Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26(10):643\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"2031_CR63","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","volume":"23","author":"E Mercuri","year":"2024","unstructured":"Mercuri E, Vilchez JJ, Boespflug-Tanguy O, Zaidman CM, Mah JK, Goemans N, et al. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024;23(4):393\u2013403.","journal-title":"Lancet Neurol"},{"key":"2031_CR64","unstructured":"Vandenborne K. Givinostat in DMD: results of the EPIDYS study with particular attention to MR measures of muscle fat fraction. Muscular Dystrophy Association Clinical & Scientific Conference; 19\u201322 March, 2023; Dallas, TX, USA, 2023."},{"issue":"1","key":"2031_CR65","doi-asserted-by":"publisher","first-page":"7108","DOI":"10.1038\/s41467-022-34831-3","volume":"13","author":"A Osseni","year":"2022","unstructured":"Osseni A, Ravel-Chapuis A, Belotti E, Scionti I, Gangloff YG, Moncollin V, et al. Pharmacological inhibition of HDAC6 improves muscle phenotypes in dystrophin-deficient mice by downregulating TGF-\u03b2 via Smad3 acetylation. Nat Commun. 2022;13(1):7108.","journal-title":"Nat Commun"},{"issue":"3","key":"2031_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102683","volume":"36","author":"KW Louie","year":"2025","unstructured":"Louie KW, Hasegawa EH, Farr GH 3rd, Ignacz AC, Paguio A, Maenza A, et al. Epigenetic small molecule screening identifies a new HDACi compound for ameliorating Duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2025;36(3):102683.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"2031_CR67","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13395-020-00251-4","volume":"10","author":"GH Farr 3rd","year":"2020","unstructured":"Farr GH 3rd, Morris M, Gomez A, Pham T, Kilroy E, Parker EU, et al. A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy. Skelet Muscle. 2020;10(1):29.","journal-title":"Skelet Muscle"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-02031-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-02031-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-02031-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:03:51Z","timestamp":1767837831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13148-025-02031-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2031"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-02031-7","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}